Retina Institute Japan, Fukuoka, develops an iPS-based cure for age-related macular degeneration. The IP is on exclusive license from RIKEN, and Dainippon Sumitomo Pharma buys for 1.500 million Yen (12 million €) on an exclusive third party agreement. Retina Institute Japan was founded only in February, 2011.
Dainippon Sumitomo Pharma press release, March 28, 2013
Dainippon Sumitomo Pharma buys all open stock of Retina Institute Japan K.K., an iPS company